At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
Prednisolone Sodium Phosphate Ophthalmic Solution 1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model
In Brief
A Phase 4 clinical trial evaluating Prednisolone Sodium Phosphate Ophthalmic Solution 1% and Tears Naturale II Ophthalmic Solution for Allergic Conjunctivitis. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: * Ocular itching * Conjunctival redness
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
Primary CompletionFeb 2012
First PostedFeb 2012
TodayJul 2026
First PostedFeb 16, 2012
Enrollment StartJan 1, 2012
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.4 years ago
Interventions
Prednisolone Sodium Phosphate Ophthalmic Solution 1%drug
One drop in each eye, four times/day for 8 days.
Tears Naturale II Ophthalmic Solutiondrug
one drop in each eye, four times/ day (QID) for 8 days